| 41.125 1.275 (3.2%) | 11-11 15:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.02 | 1-year : | 59.6 |
| Resists | First : | 43.68 | Second : | 51.02 |
| Pivot price | 39.61 |
|||
| Supports | First : | 38.07 | Second : | 34.61 |
| MAs | MA(5) : | 39.94 |
MA(20) : | 39.23 |
| MA(100) : | 26.47 |
MA(250) : | 21.01 |
|
| MACD | MACD : | 1.5  |
Signal : | 1.8 |
| %K %D | K(14,3) : | 46 |
D(3) : | 43.6 |
| RSI | RSI(14): 60.2 |
|||
| 52-week | High : | 43.68 | Low : | 9.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARWR ] has closed below upper band by 31.0%. Bollinger Bands are 5.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.06 - 42.3 | 42.3 - 42.51 |
| Low: | 39.16 - 39.46 | 39.46 - 39.74 |
| Close: | 39.42 - 39.85 | 39.85 - 40.24 |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Thu, 06 Nov 2025
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results - Business Wire
Thu, 06 Nov 2025
Arrowhead Pharmaceuticals (ARWR): Exploring Valuation After a 7% Climb and Strong Year-to-Date Gains - Sahm
Tue, 04 Nov 2025
How Arrowhead Pharmaceuticals Inc. (ARWR) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Tue, 04 Nov 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences - Business Wire
Wed, 29 Oct 2025
Arrowhead Pharmaceuticals (ARWR): Exploring Valuation After Shares Surge Over 20% This Month - Sahm
Tue, 21 Oct 2025
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 138 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 78 (%) |
| Shares Short | 11,650 (K) |
| Shares Short P.Month | 11,860 (K) |
| EPS | -1.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.77 |
| Profit Margin | -25.9 % |
| Operating Margin | -596.3 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -37.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 4.14 |
| Sales Per Share | 4.14 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 22 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -33.94 |
| PEG Ratio | 0 |
| Price to Book value | 10.77 |
| Price to Sales | 9.82 |
| Price to Cash Flow | 257.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|